News

Mission
The Impact Journals news page hosts articles about important news stories from our journals and within the scientific community. Visit this page for the latest in medical advances, pharmaceutical progress, conference reports, and more.

Downregulation of Angulin-1/LSR Induces Malignancy in Lung Adenocarcinoma

News

March 29, 2023
PRESS RELEASE: On March 24, 2023, a new research paper was published in Oncotarget, entitled, “Downregulation of angulin-1/LSR induces malignancy via upregulation of EGF-dependent claudin-2 and TGF-β-dependent cell metabolism in human lung adenocarcinoma A549 cells.” continue reading »

Oncotarget | Polyisoprenylated Cysteinyl Amide Inhibitors Deplete G-Proteins in Cancer Cells

News

March 28, 2023
PRESS RELEASE: On March 24, 2023, a new research paper was published in Oncotarget, entitled, “Polyisoprenylated cysteinyl amide inhibitors deplete singly polyisoprenylated monomeric G-proteins in lung and breast cancer cell lines.” continue reading »

Aging | Parsing Chronological and Biological Age Effects on Vaccine Responses

Aging

March 27, 2023
PRESS RELEASE: Researchers Chris P. Verschoor and George A. Kuchel from Health Sciences North Research Institute published a new editorial in Aging, entitled, “Parsing chronological and biological age effects on vaccine responses.” continue reading »

Genes & Cancer | VCP/p97 as a Therapeutic Target in KRAS-Mutant Pancreatic Cancer

News

March 24, 2023
PRESS RELEASE: On March 10, 2023, a new research paper was published in Genes & Cancer, entitled, “VCP/p97, a pleiotropic protein regulator of the DNA damage response and proteostasis, is a potential therapeutic target in KRAS-mutant pancreatic cancer.” continue reading »

Oncotarget | Attenuation of Cancer Proliferation by Suppression of Glypican-1

Oncotarget

March 22, 2023
PRESS RELEASE: On March 21, 2023, a new research paper was published in Oncotarget, entitled, “Attenuation of cancer proliferation by suppression of glypican-1 and its pleiotropic effects in neoplastic behavior.” continue reading »